The expiration of enhanced ACA subsidies resets market dynamics, reshaping enrollment patterns and risk pools across the individual market.

Gene therapies for sickle cell disease show promise, but broad access requires more collaboration among manufacturers, payers, and healthcare systems.

For estimating benefit richness in the individual ACA market, we demonstrate advantages of using Milliman's model over the Federal Actuarial Value Calculator.

We present our key findings from a look at healthcare utilization among Medicare fee-for-service beneficiaries living in historically redlined neighborhoods.

Among commercially insured members, we examine how overdoses correlate with the utilization of psychotropic and other select nervous system prescription drugs.

ACA subsidy increases translate to more affordability and new opportunities for carriers.

This paper examines the evolution and future of preventative services—a key component of many health insurance plans.

This report provides analysis and commentary on relevant considerations when evaluating the appropriateness of various databases and methods to establish reference prices in surprise billing situations.

Screening and risk assessment are critical to exercising sound clinical judgment and making effective care decisions regarding opioid use disorder.